Price
No data yet.
Social Signal Score
Revenue
$28.9K-93.62%Company Profile
- CEO
- Michael K. Korenko
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1
- Beta
- -0.71
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.65
Financials
Revenue
$28.9K-93.6%Net Income
$-731.6K-352.9%EBITDA
$-741.4K-112.3%Free Cash Flow
$-745.1KEPS (diluted)
$-0.00-101.7%Shares Outstanding (diluted)
494.29M+15109.0%Operating Expenses
$619.9KCash & Debt
$1.81MReturn of Capital
$0.00Revenue by Segment (annual)
$2.1KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $68.4K | $-3.07M | $-0.01 |
| 2024 | $28.0K | $-2.91M | $-0.01 |
| 2023 | $19.5K | $-2.90M | $-0.01 |
| 2022 | $36.5K | $-2.47M | $-0.01 |
| 2021 | $14.9K | $-2.53M | $-0.01 |
| 2020 | $7.0K | $-957.0K | $-0.00 |
| 2019 | $9.5K | $-1.61M | $-0.01 |
| 2018 | $0.00 | $-7.70M | $-0.14 |
| 2017 | $4.1K | $-6.42M | $-1.06 |
| 2016 | $8.1K | $-9.86M | $-3.67 |
| 2015 | $24.1K | $6.23M | $2.72 |
| 2014 | $24.1K | $-18.11M | $-45.38 |
| 2013 | $140.6K | $-3.47M | $-27.58 |
| 2012 | $248.0K | $-8.59M | $-90.77 |
Valuation
RDGLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (13)
- Newsglobenewswire.com·6d ago·Negative
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders' equity requirement
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
…nsion of IsoPet® Animal Cancer Division with Four New Veterinary Clinics Across the United States Kennewick, WA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased to announce continued expansion of its IsoPet® Animal Cancer Division, with four additional veterinary facilities advancing through the certification, licensing, and onboarding process to offer IsoPet® …
View source ↗ - Newsglobenewswire.com·32d ago·Positive
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders' Equity Standard LITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter
View source ↗ - Newsglobenewswire.com·34d ago·Positive
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue an
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test Transaction Expected to Increase Stockholders' Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances Transaction Expected to Increase Stockholders' Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
Vivos Therapeutics Announces Material Debt Reduction LITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered into twelve exchange agreem
View source ↗ - Newsnewsfilecorp.com·82d ago·Positive
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructive sleep apnea (OSA) and related breathing and sleep disorders, today announced that Founder and Chief Executive Officer R. Kirk Huntsman will presen
View source ↗ - Newsglobenewswire.com·86d ago·Positive
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center LITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related
View source ↗ - Newsglobenewswire.com·89d ago·Neutral
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers LITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced that new OSA patient referral
View source ↗ - Newsglobenewswire.com·96d ago·Negative
…nd Authorization from India's Nuclear Regulatory Authority for International Manufacturing Center Kennewick, WA, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, today announced two significant operational milestones: the commencement of IsoPet® shipments from its new in-house U.S. production facility, and the receipt of authorization from The Atomic Energy Regulatory Boar…
View source ↗ - Newsglobenewswire.com·100d ago·Positive
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update Quarter highlighted by steadily increasing patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing inn
View source ↗ - Newsglobenewswire.com·100d ago·Positive
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, announced it plans to release
View source ↗
Insider trading
Open-market buys and sells by RDGL officers and directors.
- Bought
- $341k
- Sold
- $25k
41 trades
11 trades
- Weeks Brad Allanbought
- Korenko Michael Kbought
- Korenko Michael Kbought
- Weeks Brad Allanbought
- Weeks Brad Allanbought
- Korenko Michael Kbought
- Weeks Brad Allanbought
- Weeks Brad Allanbought
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RDGL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
